ArticleAmerican journal of translational research2025
Factors influencing pathological response after neoadjuvant therapy for advanced gastric cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence in Gastric Cancer: Diagnostic, Prognostic, and Predictive Developments, Evidence Maturity, and Translational Challenges.Cancer reports (Hoboken, N.J.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify the factors influencing pathological responses after neoadjuvant therapy in advanced gastric cancer and to construct an effective prediction model for an improved response.
methodsClinical data from 100 patients with advanced gastric cancer who received neoadjuvant therapy at The Fifth Hospital of Wuhan from January 2020 to December 2023 were retrospectively analyzed. Basic data, laboratory test results, and other patient information were collected. Univariate and multivariate logistic regression were used to analyze the factors influencing good disease recovery after neoadjuvant therapy. Based on the results of multi-factor analysis, a nomogram risk prediction model was constructed, and its effectiveness was validated. The model's discriminatory power was assessed using the receiver operating characteristic curve (ROC) and the area under the ROC curve (AUC), while its fit was evaluated using a calibration curve. The model's consistency was assessed using the Hosmer-Lemeshow (HL) test.
resultsAmong the 100 patients, 22 (22%) had a good pathological response. Multivariate analysis showed that tumor differentiation, carcinoembryonic antigen (CEA), longest tumor diameter, and cN stage were significant factors influencing the pathological response of patients after neoadjuvant therapy. Based on the above indicators, a nomogram prediction model was constructed, with the following formula: Logit (P) = -1.653 + 1.562 × (tumor differentiation degree) + 1.925 × (CEA) + 1.620 × (longest tumor diameter) + 1.483 × (cN stage). The AUCs of the training set and the test set were 0.884 (95% CI: 0.778-0.990) and 0.861 (95% CI: 0.709-1.000), respectively. The HL test showed good fit (χ
conclusionTumor differentiation, CEA, longest tumor diameter, and cN stage are significant factors influencing the pathological response to neoadjuvant therapy in advanced gastric cancer. The prediction model developed based on these factors demonstrates good predictive performance and may aid in clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.